CNSX:BUX

(BUX) Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume11,500 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

(BUX) (CNSX:BUX) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying BUX stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to (BUX), including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Akumin (TSE:AKU) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Earnings & Valuation

This table compares Akumin and (BUX)'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminC$246.08 million1.10$-25,263,475.00C($0.37)-10.71
(BUX)N/AN/AN/AN/AN/A

(BUX) has lower revenue, but higher earnings than Akumin.

Profitability

This table compares Akumin and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
(BUX)N/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akumin and (BUX), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin01102.50
(BUX)0000N/A

Akumin presently has a consensus target price of C$4.25, indicating a potential upside of 8.70%.

Summary

Akumin beats (BUX) on 2 of the 2 factors compared between the two stocks.

(BUX) (CNSX:BUX) and LexaGene (CVE:LXG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Analyst Ratings

This is a summary of current recommendations for (BUX) and LexaGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
LexaGene0000N/A

Valuation and Earnings

This table compares (BUX) and LexaGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
LexaGeneN/AN/AN/AC($0.12)-6.22

Profitability

This table compares (BUX) and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
LexaGeneN/AN/AN/A

(BUX) (CNSX:BUX) and SQI Diagnostics (CVE:SQD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Profitability

This table compares (BUX) and SQI Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
SQI DiagnosticsN/AN/AN/A

Earnings & Valuation

This table compares (BUX) and SQI Diagnostics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
SQI DiagnosticsC$977,000.00108.10C$-12,264,984.00C($0.04)-8.61

(BUX) has higher earnings, but lower revenue than SQI Diagnostics.

Analyst Ratings

This is a summary of recent ratings for (BUX) and SQI Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
SQI Diagnostics0000N/A

Summary

SQI Diagnostics beats (BUX) on 1 of the 1 factors compared between the two stocks.

Sernova (CVE:SVA) and (BUX) (CNSX:BUX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Sernova and (BUX), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
(BUX)0000N/A

Profitability

This table compares Sernova and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/AN/AN/A
(BUX)N/AN/AN/A

Valuation and Earnings

This table compares Sernova and (BUX)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/AN/AC($0.03)-55.19
(BUX)N/AN/AN/AN/AN/A

(BUX) (CNSX:BUX) and GeneNews (TSE:GEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares (BUX) and GeneNews' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

(BUX) has higher earnings, but lower revenue than GeneNews.

Profitability

This table compares (BUX) and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
GeneNewsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for (BUX) and GeneNews, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
GeneNews0000N/A

Summary

GeneNews beats (BUX) on 1 of the 1 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for LED Medical Diagnostics and (BUX), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
(BUX)0000N/A

Profitability

This table compares LED Medical Diagnostics and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
(BUX)N/AN/AN/A

Earnings & Valuation

This table compares LED Medical Diagnostics and (BUX)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04$-1,512,615.00C($0.04)-10.26
(BUX)N/AN/AN/AN/AN/A

(BUX) has lower revenue, but higher earnings than LED Medical Diagnostics.

Summary

LED Medical Diagnostics beats (BUX) on 1 of the 1 factors compared between the two stocks.


(BUX) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.7$3.91flatC$270.63 millionC$246.08 million-10.71
LXG
LexaGene
0.5$0.74flatC$83.27 millionN/A-6.22News Coverage
SQD
SQI Diagnostics
0.9$0.31flatC$52.59 millionC$977,000.00-8.61Gap Up
SVA
Sernova
0.5$1.49flatC$31.35 millionN/A-55.19News Coverage
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40flatC$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.57flatC$5.58 millionC$37,517.00-17.27News Coverage
IDL
Imaging Dynamics
0.4$0.08flatC$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04flatC$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05flatC$795,000.00N/A-7.50Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.